^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
02/16/2021
Excerpt:
PD-L1 expression positive (≥50%)…squamous cell carcinoma…Useful in certain circumstances...Nivolumab + ipilimumab
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
02/16/2021
Excerpt:
PD-L1 expression positive (≥50%)…squamous cell carcinoma…Other recommended...Nivolumab + ipilimumab + paclitaxel + carboplatin
Secondary therapy:
carboplatin